When CDC Vaccine Guidance and Doctors’ Advice Diverge

Last updated 20 hours ago. Our resources are updated regularly but please keep in mind that links, programs, policies, and contact information do change.

Federal vaccine guidance and a doctor’s advice do not always match. Under guidance for the 2026-2027 season, the Centers for Disease Control and Prevention (CDC) recommends COVID vaccination for all adults and for children with moderately or severely weakened immune systems. For all other children, it recommends the vaccine through shared clinical decision-making, a choice made with a clinician and with no default. The American Academy of Pediatrics recommends the vaccine for everyone ages 6 through 23 months.

Medical societies write their own recommendations, separate from the federal schedule. The disagreement does not decide who pays: private insurance generally must cover vaccines on CDC’s schedule without charging the patient, including those left to an individual decision.

One vaccine, several kinds of authority

The Food and Drug Administration (FDA) evaluates a vaccine’s safety, effectiveness and manufacturing quality before deciding whether to license it for an intended population. A license lets the maker sell the vaccine for that use; it does not decide who should be advised to get it.

The FDA also says healthcare providers generally may prescribe an approved drug for an unapproved use when they judge it medically appropriate for the patient. A use outside the approved one is called off-label, and a clinician recommending it does not make it FDA-approved.

The Advisory Committee on Immunization Practices (ACIP) advises the CDC director, and its recommendations become official policy only once they are adopted by CDC. Its evidence framework considers benefits and harms, evidence quality, affected people’s values and preferences, and economic analyses.

How COVID recommendations changed

For the 2024-2025 season, ACIP recommended an FDA-approved or authorized COVID vaccine for everyone 6 months or older, consistent with the product’s license or emergency authorization. On May 27, 2025, Health Secretary Robert F. Kennedy Jr. ordered CDC to stop recommending COVID vaccination for pregnant women and healthy children, according to a federal district court’s account in a lawsuit described below. The court said CDC partially carried out the order by removing the COVID recommendation for pregnant women from its schedule and changing the recommendation for children from routine vaccination to shared clinical decision-making, without consulting ACIP.

At its September 2025 meeting, ACIP voted to move COVID recommendations for adults and children from routine vaccination to shared decision-making. CDC’s October 6, 2025 announcement said its adult and child schedules would apply individual-based decision-making after Acting Director Jim O’Neill approved the recommendations. In that announcement, O’Neill argued that individual-based decision-making would restore conversations about vaccine risks and benefits for the individual patient or parent. Those announcements explain the advice families heard in 2025, but they do not show what applies today.

CDC’s guidance for the 2026-2027 season says the July 2025 schedule’s COVID recommendations remain in effect for the 2026-2027 season because of legal uncertainties and inquiries. Its current categories recommend vaccination for all adults 18 or older and children 6 months through 17 years with moderate or severe immunocompromise, while other children use shared clinical decision-making. Immunocompromise means a weakened immune system caused by a medical condition or immune-suppressing treatment. The September 2025 COVID vote was among the committee votes the judge stayed; CDC now directs readers to the earlier July schedule instead of that later all-ages shared decision-making policy. The July 2025 schedule predates ACIP’s September 2025 vote, so an older page or news story describing the October 2025 policy, individual decisions at every age, no longer matches CDC’s current categories.

Why medical societies can disagree

The American Academy of Pediatrics (AAP) follows its own immunization policy; its Committee on Infectious Diseases writes the Red Book, which serves as AAP policy. So the federal schedule is not the only guide a pediatrician can follow.

For the 2026-2027 season, AAP recommends COVID vaccination for all children 6 through 23 months, with separate recommendations for older children based on risk, vaccination history, household circumstances or a parent’s desire for protection. Kristina Bryant, a University of Louisville pediatrics professor and a member of the AAP’s Committee on Infectious Diseases, told the Association of American Medical Colleges in its October 1, 2025 guide, updated October 6, that the youngest children are at risk for more severe infection.

CDC’s pregnancy page, updated October 8, 2026, recommends a 2026-2027 COVID vaccine for all adults 18 or older and identifies pregnancy as a condition that increases the benefit of vaccination. A pregnant adult is therefore included in that all-adults recommendation; the coverage rules and plan exceptions below still determine payment.

CDC’s table for vaccinating pregnant women, dated August 22, 2025, lists COVID vaccination as “No guidance/not applicable,” while its general clinical guidance recommends vaccination for all adults. An entry giving no pregnancy-specific guidance is not a recommendation against vaccination.

The American College of Obstetricians and Gynecologists (ACOG) continues to recommend routine updated COVID vaccination for people who are pregnant, contemplating pregnancy, recently pregnant or lactating. ACOG cites pregnancy-related disease risk and accumulated vaccine safety evidence, and says vaccination should be standard preventive care rather than deferred solely to neutral shared decision-making. That is ACOG’s clinical position; it does not change the federal schedule or what an insurer must cover.

CDC’s current guidance says all patients should discuss the benefits and risks of COVID vaccination with their healthcare providers to make informed, personalized decisions.

What shared decision-making changes

Under CDC’s definitions, routine, catch-up and risk-based recommendations carry a default: vaccinate the eligible person unless a medical reason makes the vaccine unsuitable. Shared clinical decision-making has no default. No default is different from a recommendation against vaccination. The decision can weigh the best available evidence of who may benefit, the person’s characteristics, values and preferences, the clinician’s judgment and the characteristics of the vaccine.

For this purpose, CDC’s definition of a provider includes physicians, physician assistants, nurse practitioners, registered nurses and pharmacists. CDC leaves it to providers to decide which eligible patients to raise these recommendations with, and says they should be open to patients who bring the subject up themselves.

FDA-approved use of Spikevax, Comirnaty, mNexspike and Nuvaxovid covers people 65 or older; younger recipients must have at least one underlying condition that puts them at high risk of severe COVID outcomes and meet the product’s minimum age. Within that younger group, FDA approves Moderna’s Spikevax from 6 months of age. Comirnaty, manufactured by BioNTech, is approved starting at age 5 for that group. Moderna’s mNexspike begins at 12 years in the same approval category. Nuvaxovid, made by Sanofi, also starts at 12 years for those younger recipients. CDC’s current guidance identifies recommended uses outside an FDA-approved indication as off-label. So a CDC recommendation for an age group does not, by itself, mean every COVID vaccine is FDA-approved for everyone in that group.

Coverage follows a different set of rules

The Affordable Care Act requires private health plans to cover immunizations with no cost sharing, such as a copayment, coinsurance or deductible, when an ACIP recommendation is in effect for the individual. CDC says this includes shared decision-making recommendations adopted by CDC and listed on its immunization schedules. Changing a recommendation’s category does not automatically remove the payment obligation. Conversely, a medical society’s advice does not alone establish that a particular insurer is legally required to pay.

That requirement does not apply to grandfathered health plans. A job-based plan keeps grandfathered status if it has continuously covered at least one person since March 23, 2010 and has not substantially cut benefits or raised costs; insurers must notify members of that status. Check the plan’s status notice or benefits administrator instead of assuming that an old plan still qualifies.

A plan with a provider network does not have to cover a preventive service from an out-of-network provider, and may charge cost sharing for it. But if no provider in its network can furnish the service, the plan must cover it out of network without cost sharing. Before relying on free coverage, check the plan’s own coverage and network rules.

The Vaccines for Children (VFC) program covers eligible children 18 or younger who are uninsured, Medicaid-eligible or enrolled, American Indian or Alaska Native, or underinsured; children enrolled in a separate Children’s Health Insurance Program are not VFC-eligible. Underinsured children have insurance gaps for vaccines, such as exclusions, coverage for only selected vaccines or an exhausted vaccine coverage cap. An underinsured child can receive VFC vaccine only through a federally qualified health center, rural health clinic or another provider authorized under an approved deputization agreement. A deputization agreement lets a federally qualified health center or rural health clinic authorize another VFC-enrolled location to vaccinate underinsured children as its agent. Federal law requires the program to use the vaccine list established and periodically reviewed by ACIP.

VFC supplies the vaccines themselves at no cost; a provider may charge an administration fee but cannot refuse vaccination because the family cannot pay that fee. Other services during the visit can still carry charges.

Medicare Part B covers FDA-approved or authorized COVID vaccines and pneumococcal vaccines with no patient cost when the provider accepts assignment. A provider who accepts assignment agrees to accept the Medicare-approved amount as full payment for a covered service.

Schedules, information sheets and state requirements

CDC’s schedule index links child/adolescent and adult schedules with addenda labeled July 2, 2025, alongside easier-to-read versions for parents and patients. Check the schedule’s notes and the vaccine-specific page together, rather than assuming the newest-looking headline settles the current rule.

The July 2 addenda record recommendations added since October 24, 2024, including a combined meningococcal vaccine option when both component vaccines are indicated at the same visit. The adult addendum also adds one RSV dose for adults 50 through 59 at increased risk of severe disease, with no repeat dose for those already vaccinated. Both addenda note the May 29, 2025 COVID changes, including changes for pregnant women; the child addendum also identifies changes for children without moderate or severe immunocompromise. CDC’s update history expressly identifies the July 2, 2025 adult and pediatric schedules as the schedules reflected in its vaccination guidance.

A Vaccine Information Statement (VIS) is a CDC document explaining a vaccine’s benefits and risks, and federal law requires the appropriate VIS before every dose of specified vaccines regardless of the recipient’s age. The COVID VIS page labels its current edition January 31, 2025, and says the page will be updated to align with the updated immunization schedule. The information sheet handed out with a vaccine is a different kind of document from a current recommendation schedule.

With pneumococcal vaccines, who should be vaccinated is one question and which product to use is another. CDC recommends pneumococcal vaccination for children younger than 5 and adults 50 or older, and for children and adults at increased risk. It lists two types of pneumococcal vaccine: the pneumococcal conjugate vaccines (PCV15, PCV20 and PCV21), and the pneumococcal polysaccharide vaccine (PPSV23). A polysaccharide vaccine uses long chains of sugar molecules resembling a bacterial surface to trigger an immune response; a conjugate vaccine joins a protein to an antigen to improve protection. The number at the end of each name tells how many strains of pneumococcal bacteria the vaccine includes. The routine childhood pneumococcal series uses PCV15 or PCV20. For adults 50 or older who have never received a conjugate vaccine or whose vaccination history is unknown, the guidance says PCV15 should be followed by a dose of PPSV23 unless PPSV23 was already received; after PCV20 or PCV21, no PPSV23 dose is called for. The number in a product’s name does not, on its own, show which recommendation applies to a person.

State laws establish school vaccination requirements and often extend them to private schools and day care; states may also require immunization of healthcare workers or residents of healthcare facilities. A CDC recommendation is not itself a new state school requirement.

What to check when the policy moves again

In American Academy of Pediatrics v. Kennedy, U.S. District Judge Brian E. Murphy granted preliminary relief in part on March 16, 2026. He stayed a January 2026 memo revising CDC’s childhood immunization schedule, the appointments of thirteen ACIP members and all votes taken by the now-stayed committee. The order describes that memo as reducing routine childhood recommendations from seventeen to eleven, limiting several vaccines to high-risk groups, and moving vaccines including rotavirus, COVID and influenza to shared decision-making. A stay pauses the challenged actions while the lawsuit proceeds; this order is not a final judgment.

On September 11, 2026, Judge Murphy put the district court case on hold until the Court of Appeals issues a decision. That court, the U.S. Court of Appeals for the First Circuit, heard oral argument on October 6, 2026. The appeal could change the legal footing of the recommendation process, so check CDC’s current pages before relying on an older announcement.

CDC’s ACIP meeting page offers public webcasts and describes written comments through Regulations.gov and oral comments at meetings, but marks its March, June and October 2026 meetings cancelled because of litigation. Check whether a meeting and comment period are open before submitting a comment.

This article was researched with AI assistance and checked against the sources cited.